Metabolic results 3 years after simultaneous pancreas–kidney transplantation
Nephrology Dialysis TransplantationPeer ReviewedAntonio Secchi +22005Journals
Simultaneous pancreas-kidney (SPK) transplantation has become accepted therapy for patients with type 1 diabetes and end-stage renal disease. This 3-year study compared the metabolic effects of tacrolimus- and cyclosporin microemulsion (ME)-based immunosuppressive therapy in this clinical setting.
The content you want is available to Zendy users.
Already have an account? Sign inHaving issues? Contact support